SCHEMBL3109618

SCHEMBL3109618

NC(=O)Oc1ccc(-c2nc3cc(F)c(OCc4c(Cl)cccc4Cl)cc3s2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.40
PPARD Q03181 2/20 0.40
PPARA Q07869 1/20 0.40
MAPT P10636 7/20 0.40
SMN1; SMN2 Q16637 6/20 0.40
RAB9A P51151 5/20 0.40
NPC1 O15118 4/20 0.40
KDM4E B2RXH2 3/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
HPGD P15428 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40
HTT P42858 1/20 0.40
ATM Q13315 1/20 0.40
NR1H4 Q96RI1 3/20 0.39
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3093465 0.85 NR1H4 (0.51) MAPTSMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL3109612 0.85 DYRK1A (0.39) FFAR1PPARDPPARAMAPTSMN1; SMN2
SCHEMBL3098705 0.85 NR1H4 (0.48) FFAR1PPARDPPARAMAPTSMN1; SMN2
SCHEMBL3093694 0.85 MAPT (0.38) FFAR1PPARDPPARAMAPTSMN1; SMN2
SCHEMBL3105460 0.84 MAPT (0.38) FFAR1PPARDPPARAMAPTSMN1; SMN2
SCHEMBL3105421 0.83 MAPT (0.38) FFAR1PPARDPPARAMAPTSMN1; SMN2
SCHEMBL3102687 0.82 MAPT (0.40) MAPTSMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL3093410 0.80 APP (0.46) FFAR1PPARDPPARAMAPTRAB9A
SCHEMBL3104412 0.77 CYP2D6 (0.43) MAPTSMN1; SMN2RAB9AKDM4EKMT2A
SCHEMBL3104495 0.76 MET (0.44) MAPTSMN1; SMN2RAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS SANOFI-AVENTIS (FR) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS MET, ALK, JAK2 FFAR1 817/4885PPARD 2611/4885PPARA 3027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.